1.北京中医药大学厦门医院 厦门市中医院,厦门 361001
2.北京中医药大学中医学院,北京 100029
3.北京 中医药大学循证医学中心,北京 100029
4.北京中医药大学岐黄学院,北京 100029
5.北京市海淀区妇幼保健院,北京 100000
6.湖北中医药大学第一临床学院 湖北省中医院,武汉430000
7.广东药科大学 广东省代谢病 中西医结合研究中心(中医药研究所),广州 510006
金信妍,女,29岁,博士,助理研究员。研究方向:中西医结合循证医学、中医药防治乳腺疾病。
裴晓华,E-mail:pxh_127@163.com
扫 描 看 全 文
金信妍,徐留燕,包熙睿,等.基于AGREEⅡ的中医防治COVID-19指南质量评价[J].北京中医药,2023,42(5):475-481.
JIN Xin-yan,XU Liu-yan,BAO Xi-rui,et al.Quality evaluation of COVID-19 guidelines for prevention and treatment of traditional Chinese medicine based on AGREEⅡ[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(05):475-481.
金信妍,徐留燕,包熙睿,等.基于AGREEⅡ的中医防治COVID-19指南质量评价[J].北京中医药,2023,42(5):475-481. DOI: 10.16025/j.1674-1307.2023.05.004.
JIN Xin-yan,XU Liu-yan,BAO Xi-rui,et al.Quality evaluation of COVID-19 guidelines for prevention and treatment of traditional Chinese medicine based on AGREEⅡ[J]. Beijing Journal of Traditional Chinese Medicine,2023,42(05):475-481. DOI: 10.16025/j.1674-1307.2023.05.004.
目的,2,评价中医防治新型冠状病毒感染(COVID-19)临床实践指南(CPGs)的质量,为临床实践提供参考。,方法,2,检索国内外中医防治COVID-19的CPGs。采用指南研究与评估工具(AGREEⅡ)评价CPGs方法学质量;系统梳理中医推荐意见是否基于证据。,结果,2,纳入11项CPGs。AGREEⅡ各领域标准化平均得分率分别为66.29%(范围和目的)、44.07%(参与人员)、32.91%(严谨性)、67.42%(清晰性)、30.97%(应用性)、和55.87%(编辑独立性)。3项CPGs推荐级别为a、4项推荐级别为b、4项推荐级别为c。纳入5项基于证据推荐的CPGs,其中强推荐清肺排毒、连花清瘟、藿香正气联合连花清瘟及中医非药物疗法。,结论,2,中医防治COVID-19的推荐意见各异,可能与制订方法学差异有关。建议临床医生谨慎地采用缺乏证据支持的治疗方案,如条件允许,可开展研究者发起的临床试验,评价中医防治COVID-19疗效与安全性。
质量评价新型冠状病毒感染长新冠综合征中成药中医非药物疗法指南
WOOLF SH,GROL R,HUTCHINSON A,et al.Clinical guidelines:potential benefits,limitations,and harms of clinical guidelines[J].BMJ,1999,318(7182):527-530.
PRONOVOST PJ.Enhancing physicians'use of clinical guidelines[J].JAMA,2013,310(23):2501-2502.
YAO L,AHMED MM,GUYATT GH,et al.Discordant and inappropriate discordant recommendations in consensus and evidence based guidelines: empirical analysis[J].BMJ,2021,375:e066045.
ARMSTRONG JJ,GOLDFARB AM,INSTRUM RS,et al.Improvement evident but still necessary in clinical practice guideline quality:a systematic review[J].J Clin Epidemiol,2017,81:13-21.
陈志强,孟文爽,韩丽荣,等.基于指南研究与评价工具Ⅱ慢性乙型肝炎管理指南的系统评价[J].医药导报,2022,41(4):532-538.
World Health Organization.Coronavirus disease(COVID-19)[EB/OL].[2022-09-26].https://www.who.int/health-topics/coronavirus#tab=tab_1https://www.who.int/health-topics/coronavirus#tab=tab_1.
国家卫生健康委员会办公厅, 国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第三版)[J].天津中医药,2020,37(1):1-3.
World Health Organization.WHO Expert meeting on evaluation of traditional chinese medicine in the treatment of COVID-19[EB/OL].(2022-03-31)[2022-09-26].https://www.who.int/publications/m/item/who-expert-meeting-on-evaluation-of-traditional-chinese-medicine-in-the-treatment-of-covid-19https://www.who.int/publications/m/item/who-expert-meeting-on-evaluation-of-traditional-chinese-medicine-in-the-treatment-of-covid-19.
于明坤,柴倩云,梁昌昊,等.新型冠状病毒肺炎中医预防及诊疗方案汇总分析[J].中医杂志,2020,61(5):383-387.
CHAN KW,WONG VT,TANG SCW.COVID-19:An update on the epidemiological, clinical,preventive and therapeutic evidence and guidelines of integrative chinese-western medicine for the management of 2019 novel coronavirus disease[J].Am J Chin Med,2020,48(3):737-762.
BROUWERS MC,KHO ME,BROWMAN GP,et al.AGREE II:advancing guideline development,reporting and evaluation in health care[J].J Clin Epidemiol,2010,63(12):1308-1311.
王吉耀,王强,王小钦,等.中国临床实践指南评价体系的制定与初步验证[J].中华医学杂志,2018,98(20):1544-1548.
靳英辉,詹庆元,彭志勇,等.新型冠状病毒肺炎药物预防、诊断、治疗与出院管理循证临床实践指南(更新版)[J].解放军医学杂志,2020,45(10):1003-1031.
LIANG N,MA Y,WANG J,et al.Traditional chinese medicine guidelines for coronavirus disease 2019[J].J Tradit Chin Med,2020,40(6):891-896.
陈志敏,傅君芬,舒强,等.儿童2019冠状病毒病(COVID-19)诊疗指南(第二版)[J].浙江大学学报(医学版),2020,49(2):139-146.
曾玫,柳龚堡.儿童新型冠状病毒感染/肺炎疑似和确诊病例快速筛查和临床实践指南[J].中国循证儿科杂志,2020,15(1):1-4.
中华中医药学会, 中国康复医学会.新型冠状病毒肺炎恢复期中西医结合康复指南(第一版)[J].天津中医药,2020,37(5):484-489.
陈韬,陈广,郭威,等.新型冠状病毒感染的肺炎诊疗快速指南(第三版)[J].医药导报,2020,39(3):305-307.
中国心理卫生协会.新型冠状病毒感染的肺炎公众心理自助与疏导指南[M].北京:人民卫生出版社,2020:17,25-29.
中华医学会呼吸病学分会,中国医师协会呼吸医师分会.中国成人2019冠状病毒病的诊治与防控指南[J].中华医学杂志,2021,101(18):1293-1356.
GE L,ZHU H,WANG Q,et al.Integrating chinese and western medicine for COVID-19:A living evidence-based guideline (version 1)[J].J Evid Based Med,2021,14(4):313-332.
LI ZY,XIE ZJ,LI HC,et al.Guidelines on the treatment with integrated traditional chinese medicine and western medicine for severe coronavirus disease 2019[J].Pharmacol Res,2021,174:105955.
国家卫生健康委员会办公厅, 国家中医药管理局办公室.新型冠状病毒肺炎诊疗方案(试行第九版)[J].心肺血管病杂志,2022,41(5):449-457.
盛永成,李莉,汪琴,等.基于AGREE Ⅱ和AGREE-China的中国脆性骨折指南与共识的质量评价[J].中国循证医学杂志,2022,22(3):351-359.
王艳国,孙武权,詹强.儿童新型冠状病毒肺炎小儿推拿干预专家共识(第一版)[J].天津中医药,2020,37(10):1114-1118.
河南省卫生健康委员会.河南省新冠肺炎防治方案[EB/OL].(2022-01-08)[2022-09-16].https://www.tcm.gov.cn/xxfb/zydt/2022/0108/1480741531643154432.shtmlhttps://www.tcm.gov.cn/xxfb/zydt/2022/0108/1480741531643154432.shtml.
ZHAO Z,LI Y,ZHOU L,et al.Prevention and treatment of COVID-19 using traditional chinese medicine:A review[J].Phytomedicine,2021,85:153308.
唐健元.新型冠状病毒疫情下的中医药社区防控技术研究[R].四川:成都中医药大学临床医学院,2021.
HE S,TIAN J,LI X,et al.Positive RT-PCR test results in 420 patients recovered from COVID-19 in wuhan:an observational study[J].Front Pharmacol,2020,11:549117.
AN X,PENG B,HUANG X,et al.Ludangshen oral liquid for treatment of convalescent COVID-19 patients:a randomized,double-blind,placebo-controlled multicenter trial[J].Chin Med,2022,17(1):42.
CHEN Y,LIU C,WANG T,et al.Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with COVID-19 infection:A multicentre,double-blind,and randomised controlled trial[J].J Ethnopharmacol,2022,284:114830.
王成祥,冯淬灵,于会勇,等.新型冠状病毒感染恢复期中医药综合干预方案(试行第二版)[J].北京中医药,2023,42(1):40-43.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构